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Abstract: Heparin is a vital pharmaceutical anticoagulant drug and remains one of the few naturally
sourced pharmaceutical agents used clinically. Heparin possesses a structural order with up to four
levels of complexity. These levels are subject to change based on the animal or even tissue sources
that they are extracted from, while higher levels are believed to be entirely dynamic and a product
of their surrounding environments, including bound proteins and associated cations. In 2008,
heparin sources were subject to a major contamination with a deadly compound—an over-sulphated
chondroitin sulphate polysaccharide—that resulted in excess of 100 deaths within North America
alone. In consideration of this, an arsenal of methods to screen for heparin contamination have been
applied, based primarily on the detection of over-sulphated chondroitin sulphate. The targeted nature
of these screening methods, for this specific contaminant, may leave contamination by other entities
poorly protected against, but novel approaches, including library-based chemometric analysis in
concert with a variety of spectroscopic methods, could be of great importance in combating future,
potential threats.
Keywords: heparin; glycosaminoglycans; spectroscopic methods; chemometrics; quality control;
analysis
1. Introduction
The anticoagulant drug heparin is one of the oldest drugs to date in clinical use and is the second
most widely used pharmaceutical drug by mass [1]. A naturally occurring carbohydrate, it is
a member of the glycosaminoglycan (GAG) family of linear, polydisperse polysaccharides that
consist of alternating amino-sugars and uronic acids [2]. Heparin chains contain motifs that bind
with high affinity to antithrombin (AT), allowing the inhibition of both factor Xa and thrombin,
and thereby the common pathway in the coagulation cascade [3,4]. Of the motifs responsible for
binding to antithrombin, the most studied is that of the pentasaccharide sequence, which has been
made synthetically as the oligosaccharide, fondaparinux sodium (Arixtra®) [5]. Fondaparinux, along
with other types of low molecular weight heparin (LMWH) drugs, primarily inhibit factor Xa and are
used therapeutically for their improved pharmacokinetics and reduced side effects over heparin [6].
Heparin activity is not limited solely to antithrombin and both are known to bind and regulate
many proteins.
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Heparin is found exclusively in the granules of mast cells, where it protects and enhances
the activities of serine proteases during degranulation; although the physiological significance of
this is not currently well understood and the true physiological role of heparin remains, to date,
unknown. [7]. Heparin and HS are associated with numerous disease states owing to their ability to
bind and regulate a multitude of distinct molecules, including histamine, cytokines (e.g., interleukins
(IL) 2 through 4), chemokines (e.g., IL-8 and PF4), growth factors (e.g., transforming growth factor beta
(TGFbeta), fibroblast growth factors (FGFs), vascular endothelial growth factor and hepatocyte growth
factor/scatter factor) and selectins (e.g., L- and P-selectin). Heparin and HS are also associated with
the protein aggregation of amyloid-beta and tau-proteins, which have been implicated in Alzheimer’s
disease. Furthermore, heparin and HS interact with numerous pathogens, including the hepatitis B
and C, human papilloma and human immunodeficiency viruses and the malaria parasite. A number of
protein binding features within heparin and HS have been proposed and the nature of these interactions
with the aforementioned proteins have been reviewed extensively in [7].
2. Heparin Structure
The fine structure of heparin remains, to date, unknown and the mechanisms that underpin
biosynthesis remain poorly understood [8,9]. Heparin biosynthesis is not template driven and distinct
classes of biosynthetic enzymes do not always modify the polysaccharide chain to completion [8].
The polydisperse and heterogeneous nature of heparin consequently presents a significant challenge
for the pharmaceutical quality control of this biomolecule.
The structure of heparin possesses increasing levels of complexity from monosaccharide
composition, through to higher orders of structure. At its simplest level, heparin is a linear chain
of repeating amino (α-D-glucosamine (GlcN)) and uronic acid (either β- D-glucuronic acid (GlcA)
or α- L-iduronic acid (IdoA)) monosaccharide building blocks, which may be variably sulphated.
The heparin backbone encompasses a disaccharide repeating unit of GlcN with either GlcA or IdoA.
GlcN may be unmodified (amine, NH2), N-sulphated (NS) or N-acetylated (NAc) and O-sulphated
at position C6 and more rarely at position C3 (6OS and 3OS, respectively) the uronate residues may be
O-sulphated at position C2 (2OS). Theoretically, 48 disaccharides are possible (Figure 1B), but usually
fewer are observed within mammalian heparin samples, the levels of which may be probed for
structural analysis (Figure 1). Typically, in excess of 70% of constituent disaccharides of heparin
are tri-sulphated and 70–80% are typically Ido2S-GlcNS,6S (Figure 1A), with the remaining 20–30%
consisting of the other less common disaccharides [2,10–12]. The average level of sulphation, for all
disaccharide units that comprise the polysaccharide chain, is often expressed as the degree of sulphation
(DoS) and this can be used as an indicator of the underlying structure of heparin, however it offers little
indication regarding the complexity of the higher-level structure. The underlying structure of heparin
is known to be tissue specific and differs between species, with individual animals of the same species
exhibiting differences. Such variations are observed throughout the molecular weight populations,
disaccharide compositions, and anticoagulant activities (Table 1, Figure 2A) [1,10,13–15].
Table 1. Structural and biological activity of heparins extracted from distinct species, based on published
results [2,15–25]. Data are expressed as “minimum–maximum (mean)”.
Ido2S-GlcNS,6S
Specific Activity IU/mg
Mw/Da
Anti-Xa Anti-IIa APTT
Porcine Mucosal Heparin 51.5–85 (68.3) 145–220 (194) 172–230 (197) 145-277 (196) 12,000–27,090 (19,002)
Bovine Lung Heparin 70–87 (79.8) 105–156 (133) 130.6–180 (153) 89–167 (139) 12,000–15,240 (14,230)
Bovine Mucosal Heparin 47.4–64.2 (54.5) 113.6–159 (134) 92.2–160.7 (126) 88.1–181 (136) 14,900–16,417 (15,439)
Ovine Mucosal Heparin 60–89.4 (75.2) 196–205 (201) 191–201 (195) 165–165 (165) 12,200–20,023 (14,773)
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Figure 1. Structure of heparin. (A) The most common disaccharide repeat found in heparin, Ido2S-
GlcNS,6S. (B) The extent of heparin disaccharide structures, where R1, R2 and more rarely, R4, may 
be O-sulphated (OS) or -OH and R3 may be either acetyl, sulphate or rarely a free amino, and the 
uronic acid may be either β-D-glucuronic acid (GlcA) or α-L-iduronic acid (IdoA). (C) 
Pentasaccharide sequence associated with antithrombin binding. The initial residue may be N-
sulphated or N-acetylated. 
An additional level of heparin complexity and that of its sister molecule heparan sulphate (HS) 
encompass charge heterogeneity across the chain and are the result of linked biosynthesis. Unlike 
heparin, HS possesses a domain structure with distinct charge densities that are a result of varying 
disaccharide constituents. Within HS there are three domains: the NA-domain, which is primarily 
un-sulphated; the mixed (NA/NS) domain, which contains un-sulphated IdoA; and the NS-domain, 
which contains primarily IdoA2S-GlcNS, all of which may contain 6OS [12,27]. The high content of 
Ido2S-GlcNS6S within heparin prevents combinatorial domain structure from forming, however 
there are motifs dispersed throughout the chain that can bind to other biomolecules. The discovery 
of a pentasaccharide sequence (containing a rare 3OS modification) consisting of GlcNAc/NS6S-
GlcA-GlcNS3S-IdoA2S-GlcNS6S (Figure 1C) affords heparin the ability to bind with high affinity to 
antithrombin and inactivate factor Xa, while a longer oligosaccharide sequence facilitates binding to 
antithrombin and sequestration of thrombin (factor IIa), resulting in a subsequent anticoagulant effect 
[28]. 
The flexibility of the pyranose rings, the ability to rotate about constituent glycosidic linkage 
regions, and the ability to form intramolecular hydrogen bonds affords heparin a further level of 
Figure 1. Structure of heparin. (A) The most common disaccharide repeat found in heparin,
Ido2S-GlcNS,6S. (B) The extent of heparin disaccharide structures, where R 1, R2 and more rarely,
R4, may be O-sulphated (OS) or -OH and R3 may be either acetyl, sulphate or rarely a free
amino, and the uronic acid may be either β-D-glucuronic acid (GlcA) or α-L-iduronic acid (IdoA).
(C) Pentasaccharide sequence associated with antithrombin binding. The initial residue may be
N-sulphated or N-acetylated.
An additional level of heparin complexity and that of its sister molecule heparan sulphate
(HS) encompass charge heterogeneity across the chain and are the result of linked biosynthesis.
Unlike heparin, HS possesses a domain structure with distinct charge densities that are a result
of varying disaccharide constituents. Within HS there are three domains: the NA-domain,
which is primarily un-sulphated; the mixed (NA/NS) domain, which contains un-sulphated IdoA;
and the NS-domain, which contains primarily IdoA2S-GlcNS, all of which may contain 6OS [11,26].
The high content of Ido2S-GlcNS6S within heparin prevents combinatorial domain structure from
forming, however there are motifs dispersed throughout the chain that can bind to other biomolecules.
The discovery of a pentasaccharide sequence (containing a rare 3OS modification) consisting of
GlcNAc/NS6S-GlcA-GlcNS3S-IdoA2S-GlcNS6S (Figure 1C) affords heparin the ability to bind with
high affinity to antithrombin and inactivate factor Xa, while a longer oligosaccharide sequence
facilitates binding to antithrombin and sequestration of thrombin (factor IIa), resulting in a subsequent
anticoagulant effect [27].
The flexibility of the pyranose rings, the ability to rotate about constituent glycosidic linkage regions,
and the ability to form intramolecular hydrogen bonds affords heparin a further level of complexity.
Association with cations alter the conformations and bond angles depend on the size and charge
of the associated cation molecule [28]. Heparin has been modelled as exhibiting a right-handed
helix with a pitch of around four residues [29–31] but, this interpretation depends on making some
simplifying assumptions to enable interpretation of the NMR data [29]. IdoA residues have been
shown to adopt 1C4, 4C1, and 2S0 ring conformers, which interchange dynamically with minimal
alteration to the glycosidic bond conformation [31–33]. The 2OS of IdoA and the presence of NAc
on the neighbouring glucosamine is thought to favour adoption of the 2S0 conformation, in part
due to a hydrogen bond between the two, stabilising the conformation [31] opposed to GlcA and GlcN
which exist almost entirely in the rigid 4C1 form [34]. The absolute arrangement of atoms in
a three-dimensional space is driven by the aforementioned features of the heparin chain [35,36] and as
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a result it is not currently possible determine the 3D structure for an entire heparin chain [37]. This high
level of complexity affords heparin the ability to interact with many distinct biomolecules, the effects
of which propagate beyond the binding region, for example upon antithrombin binding, the entire
population of IdoA that is in the 2S0 configuration within the heparin chain increases, despite the fact
that not all of iduronates are involved directly in antithrombin binding. This is thought to enable tighter
binding at the binding site, while in heparin: FGF-1 and -2 binding, the 1C4 conformer population is
favoured, as 6OS and not IdoA2S is relevant to FGF binding [33].
Heparin coordinates readily with cations owing to its high negative charge, with the native cation
forms of heparin present within a given physiological or pathological system largely unknown. It is
assumed to be a mixture of Na+ and Ca2+, due to their high molarities in serum, however K+ ions
may bind cooperatively with Na+ [28]. Cations appear to stabilise the ring structures permeating
heparin into specific forms, homogenising bond-angles and conformer populations, resulting in altered
conformational states across the molecule. For pharmaceutical use heparin is prepared in Na+ and Ca2+
forms for parenteral administration, but Li+ form may also be utilised as coatings for medical devices.
Aside from these, many different cation forms of heparin have been studied [28,38,39]. Cations with
higher charge intuitively bind with higher affinity to heparin [28], but atomic radii regardless of charge
may impact the ability to coordinate with heparin.
Potentially, a higher additional level of heparin structure, whereby interactions between distinct
heparin chains could occur. While there would appear to have been little/no direct studies to
date of this phenomenon, the fact that heparins interact with many other molecules, coordinate
with cations, and form intramolecular hydrogen-bonds, the potential exists for heparin to form
intermolecular hydrogen bonds, share coordination with cations, and ultimately possess this level of
structural complexity.
As described above, the structural complexity of heparin is incredibly high, and therefore quality
control is very difficult. All levels of a heparin structure can and do affect spectral and activity data;
a perfectly reasonable pharmaceutical heparin may simply be in a strange cation form and therefore
exhibit unusual activities or spectral features. Further compounding this, there exists no way to
fully sequence heparin chains and thus intuitively discover molecule binding motifs of interest [40].
Furthermore, binding motifs that are known (such as the pentasaccharide sequence) require wholesale
changes of the heparin chain to bind tightly, the ramifications of which are not fully understood [12].
Heparin synthesis is also relatively misunderstood: the enzymes and the steps they catalyse are well
documented, but the reasons they do not go to completion (producing different domains and motifs, etc.)
are as yet poorly understood. To compound this, carbohydrate synthesis is not template-driven and can
alter depending on the conditions and status of the parent cell. As such, man-made, synthetic heparin
that is comparable to natural heparin is currently unviable. Therefore, pharmaceutical heparin is
a natural product, usually obtained from porcine or bovine intestine, but can be sourced from ovine
intestine and bovine lung as well; however, owing to bovine spongiform encephalopathy (BSE)
in the late 1980s and early 1990s, heparin from porcine intestinal mucosa is used predominantly
in Europe and North America. This means that commercially sourced heparin (for drug markets
or research) is naturally heterogeneous and was therefore regulated and controlled primarily based on
its relative biological activity, not by its structural composition [41].
3. Original Screening Techniques for Pharmaceutical-Grade Heparin
Early monographs were aimed at establishing whether a given sample possessed the same
anticoagulant activity as a known control, hence, heparin quality control was primarily focused on
assaying for biological activity, assuming that anything with comparable anticoagulation potential of
sufficient potency was acceptable as pharmaceutical-grade heparin. A simple clotting test (the activated
clotting time (ACT)) was prescribed, although this approach essentially overlooked the subtleties
and complexity of heparin and proved easy to circumvent with alternative entities [42,43].
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4. Contamination of Pharmaceutical Heparin, 2007–2008
Potency as a screening method possessed a fatal flaw; it assumed that the heparin being assayed
was pure heparin and that a contaminated sample would possess a lower potency and therefore fail
the screen. The limitations of this assumption were exposed in 2007–2008 when batches of heparin
demonstrated severe, adverse side effects, resembling the symptoms of anaphylaxis, which were later
established to be dual activation of the contact system [44,45]. This resulted in greater than 100 fatalities
in North America alone. Identification of the contaminant proved a considerable challenge, but through
a concerted effort of numerous laboratories, utilising nuclear magnetic resonance (NMR), capillary
electrophoresis (CE), and optical rotation, a contaminant possessing a related structure to heparin, a high
sulphation level and anticoagulant activity was discovered: that of an over-sulphated chondroitin
sulphate (OSCS) [41,46]. In this instance, the OSCS was produced by sulphate augmentation upon
a chondroitin sulphate precursor, leading to an over-sulphated (sulphated at every available hydroxyl
position) chondroitin sulphate with an average DoS of four. Due to the unusually high number of
associated side-effects, it was posited that more than one contaminant was present in pharmaceutical
heparin. It was proposed that other GAGs that may be present during the crude extraction process
may also have been over-sulphated and formulated with the final crude products thereby possessing
an unnaturally high DoS, albeit with a similar anticoagulant effect to that of “pure” heparin, however
this has not been confirmed [45].
5. Changes to the Heparin Monograph Post-Contamination
Following the heparin contamination, new techniques aimed at confirming the identity of heparin
prior to potency screening were made mandatory, resulting in the addition of two techniques to
the heparin United States pharmacopeia (USP) monograph and to the monographs of many other
pharmacopoeias namely 300 MHz 1H NMR spectroscopy [47] and capillary electrophoresis (CE) [48–50]
1H NMR offers a high-resolution technique that can demonstrate the presence of contaminants.
Most, if not all, of the major heparin 1H NMR signals have been assigned with 16 characteristic peaks
routinely used to confirm the presence of heparin in the sample. [51,52]. Changes to, or a lack of, any of
these peaks may indicate a contaminant or a suboptimal heparin sample. Due to the high charge
density of heparin and other GAGs, they are amenable to electrophoretic migration and separation
when placed within an electric field [43,53]. Separation by capillary electrophoresis may be considered
similar to that of the reversed-phase high-performance liquid chromatography (HPLC) technique,
but through use of narrow capillaries, allows for very small sample quantities to be separated. As OSCS
(or any over-sulphated, GAG contaminant) has a larger DoS compared to heparin, it will migrate in
a distinct manner within the electric field and thus can be separated [49]. Both techniques can detect
OSCS contamination at the level of 0.5% and 1%, respectively [49,54,55] and have been introduced into
the USP monograph. NMR and CE are orthogonal techniques that elucidate different components
within the structure of heparin. Hence, features of heparin that may be overlooked in one technique
will be observed within the other [56,57]. For example, unusual sequences that resist enzymatic
digestion will be poorly resolved or ignored entirely in separation techniques but may be detected by
NMR [58], thereby providing a more robust form of quality control.
Since the addition of NMR and CE in 2008, the monograph has been updated [48], prescribing
a higher field strength, that of a 500 MHz NMR spectrometer. This increases the spectral resolution
of the spectrum and therefore its discriminatory power. Strong anion exchange high-performance
liquid chromatography (SAX-HPLC) has replaced CE on the monograph as this technique affords
improved separation of potential contaminants, is more universally available, requires less-specialised
training, and does not suffer from reproducibility issues that have been shown to plague CE [51].
Size definition of the heparin chains has also been incorporated to promote an additional measure of
heparin consistency, with acceptable heparin possessing no more than 20% of its population exceeding
24,000 Da; an average molecular weight (MW) between 15,000 and 19,000 Da and a ratio of populations
between 8000: 16,000 and 16,000:24,000 Da of no less than 1.0 [6,52]. The upper limit exists to diminish
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potential side effects associated with higher MW larger chains [59], while the average exists to ensure
good potency and the ratio serves to prevent blending of failed heparin lots with accepted ones [6]. It is
important to note however, that side effects associated with larger heparins have only been seen when
comparing full-length heparin to LMWH and may not be due entirely to chain length [6]. Examples of
these techniques, including both bona fide heparin and contaminated samples can be found in Figure 2.
The clotting assays were also revised, opting for the AT: factor Xa and AT: factor II chromogenic assay,
which have a higher specificity for heparin bioactivity.
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Figure 2. Examples of the current methods used for heparin quality control. (A) Proton nuclear
magnetic resonance (NMR). (B) Strong anion exchange high-performance liquid chromatography
(SAX-HPLC chromatogram). (C) Size exclusion chromatogram showing molecular weight distribution
profile. OSCS: over-sulphated chondroitin sulphate.
6. Alternative Techniques that May Assist in Heparin Quality Assurance
Alongside the techniques employed within the heparin monograph, there are a multitude of other
techniques that are well documented for the study of heparin that may be applied to its quality control
and can be broadly separated into three orthogonal methodologies: species separation, structural
elucidation, and size definition.
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6.1. Species Separation
Electrophoretic separation has already been used in the heparin monograph in the form of CE,
where detection of OSCS and dermatan sulphate (DS) (a common impurity in heparin) at the levels
of 0.05% and 0.1%, respectively, have been achieved [49,60–62]. Alternative electrophoretic formats
such as polyacrylamide gel electrophoresis (PAGE) has also been used to distinguish OSCS from
heparin post nitrous acid treatment, a procedure that affects NS groups found in heparin but not OSCS,
allowing for their separation [55]. PAGE separation using this method relies on the contaminant to not
be N-sulphated, and thus may not be used when prior knowledge of the contaminant is unknown,
however it has detected OSCS contamination at the level of 0.1%, whilst being low-cost and facile
for performance in most labs [63]. Agarose gel electrophoresis has also been applied, with 1% OSCS
detection reported [53,64].
Chromatographic methods are in use for 42nd heparin monograph in the form of SAX-HPLC,
but there are numerous alternatives that may be of use, as reviewed in [22]. Retention by SAX is based
on competition between the analyte with counter-ions in the mobile phase, whereby analytes with
small charge/size ratios will elute first. Weak anion exchange (WAX)-HPLC, where the competitive
counter-ions are part of the stationary phase, has also been applied to heparin quality control.
SAX-HPLC can detect 0.02%–0.1% OSCS [22,51] while WAX-HPLC can detect OSCS at the level of 0.5%,
with questionable detection at 0.25% [65]. SAX-HPLC still remains the monograph-approved option,
however WAX-HPLC provides the ability to trap OSCS oligosaccharides on the column, redirecting
heparin to waste-allowing multiple injections of the same sample to reveal low OSCS contents [63].
Reversed-phase ion-pair (RPIP)-HPLC has also been used, where ion-pairing reagents are introduced
to the mobile phase, modifying the retention of a charged analyte to a hydrophobic stationary
phase. RPIP-HPLC is particularly suited to saccharide analyses of samples, where individual di-, tri-,
and tetra saccharide levels can be determined. Due to the unnatural sulphation of OSCS, it resists
digestion by conventional enzymes and therefore does not depolymerise into its saccharide constituents,
allowing easy detection and resulting in reduced peak integrals on RPIP chromatograms. This effect is
unique, however to OSCS, and other more GAG-like contaminants or impurities will be digestible,
but their constituent saccharides can then be detected. Hydrophilic interaction chromatography (HILIC)
where oligosaccharides are separated based on their overall polarity has also been used and can
separate 1% OSCS contamination, with an estimated lower level at 0.2% [66,67]. Chromatographic
methods are useful in quality control as they can separate many possible contaminants, assuming
they can be separated by the desired method. Unusual chromatograms may be indicative of novel
contaminants and hence they can be used proactively. These techniques suffer however when separating
contaminants or impurities with similar primary structures, as they may have the same underlying
structural features.
Methods of separation lend themselves to further coupling in the form of downstream detection
methods, such as mass spectrometry (MS) [63,68], fluorescent detection [53,69], and additional size
definition [70]. MS methods can be employed downstream, post-depolymerisation and separation by
other means [71,72] but they may also be employed to separate whole heparin molecules and other
GAGs [73]. Multiple ionization techniques have been utilised [74]. Generally, depolymerisation
performed as part of the MS ionisation procedure offers challenges, as S–O bonds are more labile than
glycosidic bonds, nevertheless the oligosaccharide fragments created by these techniques are relatively
well documented, hence unknown or unusual fragments, corresponding presumably to contaminants
can be identified and quantified accordingly, whilst also facilitating a higher throughput [73,75].
Performing hyphenated separations using established methods allows an increase to the sensitivity
of the individual methodologies, for example HILIC and RPIP-HPLC separation coupled to MS has
detected 0.1% and 0.5% OSCS contamination [76,77].
MS is expensive and technically challenging when compared to the methods it is hyphenated
downstream of, and so other methods to increase the sensitivity of the initial separation strategies
have been explored, typically involving the labelling of depolymerised saccharides, to allow for
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increased sensitivity of detection [78]. Typically, 2-aminoacridone (AMAC) has been used as it affords
significantly increased detection compared to that of UV. Other fluorescent tags have been utilised,
such as 4,4-Difluoro-5,7-Dimethyl-4-Bora-3a-4a-Diaza-s-Indacene-3-Propionic Acid, Hydrazide), to tag
and detect heparin disaccharides, expansion of which to other GAG species is possible and would
allow for detection of heparin and GAG contaminants [69]. Labelling techniques have been applied to
chromatography, CE, PAGE, and MS, improving all of their sensitivities [66].
Further separation of depolymerised species is another avenue of considerable interest; impurities
such as over sulphated heparan sulphate (OSHS) may respond very similarly to heparin during
separation as they possess similar charge densities and disaccharides, separation of which is very
difficult due to their similar charge densities, polarities, and hydrophobicity. Isoelectric focusing is
one method that has been used to further separate these as described in [70]. If such a method could
be coupled in a 2-dimensional manner to conventional PAGE, a very fast and cheap quality control
method could be developed.
6.2. Structural Elucidation
While 1H NMR spectroscopy is a part of the heparin monograph due to its high resolution
and complete peak assignment, there are many other ways that NMR spectroscopy could be
utilised, for example employing 13C nucleus, which is able to distinguish identical chemical features
located in distinct saccharide sequences [79]. 15N NMR has also been studied, with some nitrogen
microenvironments being assigned, producing fingerprints of intact and modified heparins [80–83].
Some contaminants such as sulphated agarose or OSHS may lurk beneath the spectrum of heparin
however, avoiding detection [84,85]. The true potential for NMR in quality control lies in powerful
higher-dimensional experiments, including homonuclear experiments such as correlation spectroscopy
(COSY) [55,86,87], total correlation spectroscopy (TOCSY) [46,80,81], heteronuclear experiments,
such as heteronuclear single-quantum correlation spectroscopy (HSQC) [46,56], heteronuclear
multiple-quantum correlation (HMQC) [56], through-space correlations such as nuclear-Over Hauser
effect spectroscopy (NOESY) [46,88], and diffusion methods such as diffusion ordered spectroscopy
(DOSY) [89]. These 2D NMR methods have been used in the study of the higher-level structure
of heparins and were pivotal in first defining OSCS as a contaminant [41,46]. Furthermore, HSQC
and HMQC using the 1H and 13C dimensions have been used to distinguish contaminants other
than OSCS, such as OSHS which possesses a very similar overall structure to heparin, while the 15N
dimension has been used to fingerprint heparins [80]. DOSY, which measures the differences between
diffusion coefficients between molecules has also been applied to detecting OSCS contamination,
showing clearly OSCS contamination and also distinguishing it from other types of contamination [89].
HSQC with SAX-HPLC have also been validated as complementary methods that may study heparin
structure and therefore its quality [90]. 2D NMR was however deemed too complex, time-consuming,
and expensive for use in the heparin monograph.
Circular dichroism (CD) is another form of spectroscopy, where a polarised electromagnetic
wave passes through a chiral substance and is able to have its right and left circularly polarised
components absorb to different extents, which is indicative of the overall topology within the studied
substance. For heparin, the IdoA and GlcA residues are diastereoisomers, which absorb the polarised
electromagnetic waves differently to each other, while oxygen atoms in glycosidic linkages, pyranose
rings, hydroxyl groups, N-sulphates, and nitrogen atoms in NAc groups also produce spectral features
in CD [34]. CD is a sensitive way to detect topological changes in heparin and has been used to
study its cation derivatives and interactions with target proteins [34,38]. CD could be used to detect
contamination, due to the alteration of normal heparin bands appearing in contaminated samples,
with down to 3.5% OSCS contamination detected when isolating wavelengths correlated to known
contaminants [91].
Vibrational spectroscopies such as infrared (IR) and Raman may also be used in heparin quality
control. Bonds within molecules vibrate at characteristic frequencies, depending on the type of bond,
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constituent atoms, and surrounding environment, all of which culminates in a unique spectrum for each
studied molecule. IR spectroscopy has previously been used to study heparin primary and secondary
structures and cation forms [30,82,83]. While IR spectroscopy studies the absorption of infrared light
into a molecule, Raman spectroscopy studies the release of the absorbed light at a different energy
level, providing similar, yet complementary, information to IR spectroscopy. When applied to OSCS
screening, 38/41 samples could be correctly identified with IR and 36/38 samples could be correctly
identified with Raman spectra, down to the level of 1.3% OSCS [58]. These methods produce spectra
with broad and overlapping bands, however they are further susceptible to environmental conditions.
6.3. Size Definition
The size definition of heparin is yet another challenging task as heparin exists as a heterogeneous
population of varying MWs. Larger heparin molecules possess increased activity but provide a larger
surface area for potential side effects to occur [6]. The size of heparin can be defined in many ways,
including legacy methods such as ultracentrifugation and viscosity measurements [86,92] and more
modern methods such as calibration through use of standards, utilising PAGE [54,87,93,94], and size
exclusion chromatography (SEC) [94–97] or through use of the Rayleigh theory, whereby the ratio of
scattered light intensity to incident light intensity is used to define MW, such as with static-right-angle-,
low-angle- and multi-angle laser light scattering (SLS, RALS, LALS, and MALS respectively)
techniques [52,88,94,98–100]. MW has also been defined using 13C NMR [101] and MS [102,103].
Size definition when compared to standards is difficult, as standards are hard to define or acquire,
meaning that they are usually created in-house, leading to variation between labs, however a USP MW
standard is available to try to reduce this [6,14,94]. A triple detector (TDA) approach has also been
utilised, where a RALS detector, a differential refractive index detector (SLS detection), and a viscometer
are used in concert to accurately define the MW of heparin and may also be used to create uniform
standards [104]. MW determination can also be used to screen for contaminants due to the resistance
of OSCS to depolymerisation by bacterial heparinises, resulting in easy detection [105].
6.4. Other Methods
Other, less conventional methods have also been applied to heparin screening. Full-length heparin
and OSCS competitively inhibit many DNA polymerases, including Taq polymerase, the enzyme used
in PCR. Therefore, the digestion of the heparin component should leave any OSCS, and subsequently
prevent the PCR from occurring. This rationale has been applied to a quick heparin screen, and as
low as 0.16% OSCS contamination has been detected [106]. A microplate-based array has also
been applied to heparin screening, taking the form of a colorimetric assay, which changes colour
depending on the molecule (full length or depolymerised heparin and OSCS for example) bound
to the cationic polythiophene polymer (3-(2-(N-(N0-methylimidazole)) ethoxy)-4-methylthiophene
(LPTP)). The colorimetric shift can be recorded, and perturbations in the shift correlating to 0.001%
OSCS have been reported [107]. Fluorescent methods have also been developed, typically taking
the form of a Förster resonance energy transfer (FRET) system, whereby some fluorescent molecule
that interacts with both heparin and OSCS is introduced to the test sample and through manipulation
of the heparin molecule, either through enzymatic depolymerisation [108–113] leaving only OSCS to
cause fluorescence, or cation modification [114] resulting in preferential binding of and subsequent
detection of OSCS. Between 0.5% and 0.0001% OSCS contamination has been detected with these
methods. The differing charge densities between heparin and OSCS have also been exploited to
help detect OSCS, whereby the electric potential across an anionic-sensitive membrane can be altered
depending on the charges of the GAGs present, and hence 0.5% and theoretically lower OSCS and DS
can be detected [115]. These techniques, while powerful, are strictly applicable to OSCS and in some
examples DS, as they rely on the unique interplay between OSCS and heparin and cannot be applied
to quality control of any other or novel foreign body.
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7. Novel Issues Facing Heparin Quality Control
While numerous techniques exist that may be used or applied to the quality control of heparin,
none of them directly combat one of the major issues in heparin analysis: its high levels of heterogeneity.
As there currently exists no heparin standard that is completely sequenced, has a uniform molecular
weight distribution, and cation form, it is very difficult to confirm the fidelity of each technique to
the samples true structure. However, pharmaceutical heparin has been in circulation since 1935 and has
caused little upset during this time, albeit for the contamination in 2008. In 2011, Rudd et al. [116]
put forward the idea of screening for a proposed heparin against a library of previously accepted
heparins and through use of the chemometric method principal component analysis (PCA). The authors
were able to create a region in the N-dimensional space where accepted heparins should fall, and thus
detect “unusual” heparin samples (i.e., those contaminated with OSCS down to the level of 3%).
Chemometric analyses are data-based methods of information extraction that break down complex
data sets into a series of comparable trends. There are many chemometric analyses that may be applied
to these libraries, which may be split broadly into two styles: trained and untrained. Trained analyses,
such as partial least squares regression (PLS), K-means clustering (KMC), and machine learning
algorithms, require a priori knowledge of acceptable groupings and subsequently form models that
can be used to interrogate unknown samples for their likelihood to fall into the pre-described groups,
for example the groups “contaminated with OSCS” and “uncontaminated or pure heparin” could be
formed and tested against. Untrained techniques, such as PCA and hierarchical clustering, require no
groupings or input from the analyst, but they may not be as powerful at discriminating samples with
known differences. Trained methods are applicable to known contaminants and can be used to increase
the sensitivity of library screening techniques, assuming there are a series of samples in the library with
known levels of the contaminant, while untrained techniques are more suited to general screening,
simply showing if samples are different or similar on the basis of the information provided.
Library-based methods however, are limited by the spectroscopy they are applied to; with NMR,
samples such as OS-agarose sulphate (OSAS) or OS-dextran sulphate (OSDxS) possess spectra that lie
beneath the heparin spectra and so are poorly detected to the level of ~10% for each [116]. Different
spectroscopic techniques have been applied to library-based chemometric methods, including IR
spectra [85] which was able to distinguish OSCS contamination down to 1% and OSAS and DxS
down to 5% and 2.5%, respectively and MS, which could potentially distinguish 0.1% OSCS
contamination [73,117]. UV spectroscopy has also been used with PCA, to detect as little as 0.1%
contamination with OSCS [118]. Trained methods offer higher sensitivity: through use of machine
learning, lower OSCS contaminations and levels of DS impurities can be detected with 1H NMR
spectra, down to 1% for both [119], while through use of PLS, 38/41 and 36/38 samples were correctly
identified down to the level of 1.3% OSCS contamination as pure or not with IR and with Raman
spectra, respectively [58].
Heparin is not limited to contamination by other molecules, its very nature means that it may
be contaminated by itself. Heparins from other animal species or tissues possess different structures
and activities (Table 1), discrimination of which is very difficult with current techniques, especially
methods that separate by disaccharides, as all heparin contains the same primary constituents,
with differing secondary structures. This is particularly pertinent in modern times, as some countries
do not use heparins from different animal sources for religious or previous medical issues such as BSE.
Library-based chemometric techniques have been applied to this too; HSQC spectral features associated
with as little as 1% bovine or ovine heparin content in porcine samples have been uncovered through
interrogation of PCA loading plots [116], and spectral distinction between the two has been shown
with both HSQC [120], HMQC [121] and IR, as well as potential discrimination down to 10% bovine
contaminated with porcine in IR [85]. Heparin species detection lends itself particularly well to trained
chemometric techniques, as distinct and well-defined groups are formed based on where the sample
was acquired from, however there seem to be few studies currently which address this.
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One of the major risk factors for heparin contamination lies in its early stages of production.
Typically, the porcine intestine is collected and processed in slaughterhouses approved by regulatory
authorities before transportation to crude heparin processing facilities, where the mucosa is removed
and, following several steps, a highly anionic GAG mixture is extracted. The mixture is filtered,
precipitated, and vacuum dried to form the substance formally known as crude heparin—a mixture,
typically comprising approximately two parts heparins and one part “other” substances, including other
unwanted GAGs such as CS, DS, or HS [41,122]. While the final steps that create pharmaceutical
quality heparin from crude heparin are performed under current good manufacturing practice (cGMP)
regulations, the traceability of the porcine intestine suppliers that create the crude heparin is poor and,
since multiple sites are used, the risk of contamination is greatly increased. There is no minimum
standard for a crude heparin, so manufacturers may wish to screen crude heparins prior to processing.
Crude samples have been studied for potential OSCS content using the same techniques required by
the monograph and they were shown able to detect 1%–10% OSCS [123]. Library-based chemometric
methods have also been applied to compositional analysis of crude heparins, grouping samples by
their impurities and levels of structural features using NMR [122], but not as of yet by levels of
OSCS contamination.
2D spectral approaches, using the approach of Noda et al., may also be of interest in the future of
contamination detection. There are two methods of 2D spectroscopy: homo- and hetero-spectroscopic.
Hetero-spectroscopic 2D analysis is when spectra are recorded following some perturbation introduced
by the analyst and regions of the spectrum are assigned to these perturbations. The perturbations
may be global, following a change in temperature or pH, or more targeted, exciting specific
molecular environments and watching how they interact with neighbouring environments as in
nuclear Overhauser effect spectroscopy (NOESY) experiments, giving detailed information as to the 3D
structures of heparin. Hetero-spectroscopic 2D approaches may also be utilised, whereby a synchronous
and an asynchronous spectrum of two different spectroscopic methods are calculated and can be used
to visualise how these spectra relate to one another. This has been applied to IR and CD spectra to
better understand the effects of Cu2+ cation binding [124]. Information regarding the 3D structure of
heparin may be helpful for future heparin screening, as features hidden within spectra or unusual
interactions or conformations that may be introduced by OS—variants of similar GAGs are currently
undetectable or poorly—detectable by other means have the potential for detection.
The power of 2D spectroscopy is highlighted with NMR [46,56,80,81,84,89,116] where multiple
approaches have been utilised to significantly increase its sensitivity. The complex nature of
2D-spectroscopy calculation and interpretation however has meant that such methods are not used for
the heparin monograph. If chemometric or other applications are applied to 2D analyses, they may
serve to reduce the complexity greatly, allowing for much easier interpretation and their potential
introduction to the monograph.
8. The Future of Pharmaceutical Heparin
Ideally, pharmaceutical quality heparin would be chemically synthesised, however the tools
and technology to do so are currently not yet available. Hexa- and dodecasaccharides serving
as mimetics for LMWHs, not full-length heparin, have been produced and examined as potential
therapeutics for Alzheimer’s disease [125]. Sulphated chain lengths higher than this are currently
challenging to obtain [126]. To overcome this hurdle chemo-enzymatic synthesis has been deployed,
whereby a chemically-synthesised precursor has been modified utilising the heparin/HS biosynthesis
enzymes. Furthermore, 3OS oligosaccharides have been chemoenzymatically synthesised and a subset of
these have biological activities comparable to natural heparin [126–128]. Both synthetic and chemoenzymatic
routes remove many of the associated issues with heparin quality control as a model heparin molecule can
be synthesised to allow for improved quality control, as well as removal of the associated socioeconomic
issues related with the use of animal-derived products. Unfortunately, the costs and time required for these
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syntheses proves unviable for the current market, nevertheless synthetic and chemoenzymatic approaches
are an important consideration for the future of pharmaceutical heparin.
9. Conclusions
The future of heparin quality control is uncertain, the current established methods work to
prevent previous issues that have arisen but seem particularly focused on defining and preventing
contamination from particular molecules such as OSCS. The incredibly complex structure of heparin
makes it difficult to screen as there are no sequenced heparin standards to compare methods to. Owing to
this, chemometric methods have become more important and the idea of a heparin library to compare
test samples against is well established in the literature [73,84,129]. There are numerous methods that
can investigate heparin quality, all of which lend themselves to library creation and subsequent analysis.
Powerful techniques such as 2D NMR spectroscopy are deemed too complex for the heparin monograph
despite their unparalleled ability to distinguish contaminants. Chemometric methods may be used to
combat this, due in part to their outputs which are easy to manage and understand, furthermore, trained
methods allow for highly sensitive detection of known contaminants and impurities. Chemometric
methods do not give a simple yes/no output however, analysts still need to inspect outputs and make
subjective conclusions based on their discretion, an area in further need of research. Application of
these methods to crude heparins is also important, as the raw starting material of heparin may be easily
contaminated due to crude heparin manufacturers disperse nature. Finally, the need for such methods
of quality control could be drastically reduced or even totally removed if a viable, entirely synthetic
heparin were able to be produced.
Author Contributions: All authors have contributed to the design and preparation of this manuscript.
Funding: The authors would like to thank the Engineering and Physical Sciences Research Council,
UK, the Biotechnology and Biological Sciences Research Council, UK, the Medical Research Council, UK
and Financiadora de Estudos e Projetos (FINEP) for financial support.
Conflicts of Interest: The funders had no role in the design, preparation, interpretation and production of this
manuscript for publication.
References
1. Van Der Meer, J.Y.; Kellenbach, E.; Van Den Bos, L.J. From farm to pharma: An overview of industrial heparin
manufacturing methods. Molecules 2017, 22, 1025. [CrossRef] [PubMed]
2. Casu, B. Structure and Biological Activity of Heparin. Adv. Carbohydr. Chem. Biochem. 1985, 43, 51–134.
[PubMed]
3. Casu, B.; Oreste, P.; Torri, G.; Zopetti, G. The structure of heparin oligosaccharide fragments with high
anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence Chemical and 13C
nuclear-magnetic-resonance studies. Biochem. J. 1981, 197, 599–609. [CrossRef] [PubMed]
4. Thunberg, L.; Bäckström, G.; Lindahl, U. Further Characterization of the Antithrombin-Binding Sequence in
Heparin. Carbohydr. Res. 1982, 100, 393–410. [CrossRef]
5. Cheng, J.W.M. Fondaparinux: A New Antithrombotic Agent. Clin. Theraoeutics 2002, 24, 1757–1769.
[CrossRef]
6. Mulloy, B.; Heath, A.; Shriver, Z.; Jameison, F.; Al Hakim, A.; Morris, T.S.; Szajek, A.Y. USP compendial
methods for analysis of heparin: Chromatographic determination of molecular weight distributions for
heparin sodium. Anal. Bioanal. Chem. 2014, 406, 4815–4823. [CrossRef]
7. Mulloy, B.; Hogwood, J.; Gray, E.; Lever, R.; Page, C.P. Pharmacology of Heparin and Related Drugs.
Pharmacol. Rev. 2015, 68, 76–141. [CrossRef]
8. Kreuger, J.; Kjellén, L. Heparan Sulfate Biosynthesis: Regulation and Variability. J. Histochem. Cytochem.
2012, 60, 898–907. [CrossRef]
9. Esko, J.D.; Selleck, S.B. Order Out of Chaos: Assembly of Ligand Binding Sites in Heparan Sulfate 1.
Annu. Rev. Biochem. 2002, 71, 435–471. [CrossRef]
Medicina 2019, 55, 636 13 of 19
10. Rabenstein, D.L. Heparin and heparan sulfate: Structure and function. Nat. Prod. Rep. 2002, 19, 312–331.
[CrossRef]
11. Stringer, S.E.; Gallagher, J.T. Heparan sulphate. Int. J. Biochem. Cell Biol. 1997, 29, 709–714. [CrossRef]
12. Casu, B.; Naggi, A.; Torri, G. Re-visiting the structure of heparin. Carbohydr. Res. 2015, 403, 60–68. [CrossRef]
[PubMed]
13. Lyon, M.; Rushton, G.; Askari, J.A.; Humphries, M.J.; Gallagher, J.T. Elucidation of the structural features
of heparan sulfate important for interaction with the Hep-2 domain of fibronectin. J. Biol. Chem. 2000,
275, 4599–4606. [CrossRef] [PubMed]
14. Bertini, S.; Risi, G.; Guerrini, M.; Carrick, K.; Szajek, A.Y.; Mulloy, B. Molecular Weights of Bovine and Porcine
Heparin Samples: Comparison of Chromatographic Methods and Results of a Collaborative Survey. Molecules
2017, 22, 1214. [CrossRef] [PubMed]
15. St Ange, K.; Onishi, A.; Fu, L.; Sun, X.; Lin, L.; Mori, D.; Zhang, F.; Dordick, J.S.; Fareed, J.;
Hoppensteadt, D.; et al. Analysis of Heparins Derived From Bovine Tissues and Comparison to Porcine
Intestinal Heparins. Clin. Appl. Thromb. 2016, 22, 520–527. [CrossRef] [PubMed]
16. Chen, J.; Yu, Y.; Fareed, J.; Hoppensteadt, D.; Jeske, W.; Kouta, A.; Caijuan, J.; Jin, Y.; Yao, Y.;
Xia, K.; et al. Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins with
Enoxaparin. Clin. Appl. Thromb. 2019, 25. [CrossRef] [PubMed]
17. Zhang, F.; Yang, B.; Ly, M.; Solakyildirim, K.; Xiao, Z.; Wang, Z.; Beaudet, J.M.; Torelli, A.Y.; Dordick, J.S.;
Linhardt, R.J. Structural characterization of heparins from different commercial sources. Anal. Bioanal. Chem.
2011, 401, 2793–2803. [CrossRef] [PubMed]
18. Jeske, W.; Kouta, A.; Farooqui, A.; Siddiqui, F.; Rangnekar, V.; Niverthi, M.; Laddu, R.; Hoppensteadt, D.;
Iqbal, O.; Walenga, J.; et al. Bovine Mucosal Heparins Are Comparable to Porcine Mucosal Heparin at USP
Potency Adjusted Levels. Front. Med. 2019, 5, 360. [CrossRef] [PubMed]
19. Guan, Y.; Xu, X.; Liu, X.; Sheng, A.; Jin, L.; Linhardt, R.J.; Chi, L. Comparison of Low-Molecular-Weight
Heparins Prepared From Bovine Lung Heparin and Porcine Intestine Heparin. J. Pharm. Sci. 2016,
105, 1843–1850. [CrossRef]
20. Bianchini, P.; Liverani, L.; Mascellani, G.; Parma, B. Heterogeneity of unfractionated heparins studied in
connection with species, source, and production processes. Semin. Thromb. Hemost. 1997, 23, 3–10. [CrossRef]
21. Mulloy, B.; Gray, E.; Barrowcliffe, T.W. Characterization of unfractionated heparin: Comparison of materials
from the last 50 years. Thromb. Haemost. 2000, 84, 1052–1056. [PubMed]
22. Fasciano, J.M.; Danielson, N.D. Ion chromatography for the separation of heparin and structurally related
glycoaminoglycans: A review. J. Sep. Sci. 2016, 39, 1118–1129. [CrossRef] [PubMed]
23. Fu, L.; Li, G.; Yang, B.; Onishi, A.; Li, L.; Sun, P.; Zhang, F.; Linhardt, R.J. Structural Characterization of
Pharmaceutical Heparins Prepared from Different Animal Tissues. J. Pharm. Sci. 2013, 102, 1447–1457.
[CrossRef] [PubMed]
24. Watt, D.K.; Yorke, S.C.; Slim, G.C. Comparison of ovine, bovine and porcine mucosal heparins and low
molecular weight heparins by disaccharide analyses and 13C NMR. Carbohydr. Polym. 1997, 33, 5–11.
[CrossRef]
25. Tovar, A.M.F.; Capillé, N.V.M.; Santos, G.R.C.; Vairo, B.C.; Oliveira, S.N.M.C.G.; Fonseca, R.J.C.; Mourão, P.A.S.
Heparin from bovine intestinal mucosa: Glycans with multiple sulfation patterns and anticoagulant effects.
Thromb. Haemost. 2012, 107, 903–915. [PubMed]
26. Turnbull, J.E.; Gallagher, J.T. Distribution of iduronate 2-sulphate residues in heparan sulphate. Evidence for
an ordered polymeric structure. Biochem. J. 2015, 273, 553–559. [CrossRef] [PubMed]
27. Bourin, M.C.; Lindahl, U. Glycosaminoglycans and the regulation of blood coagulation. Biochem. J. 2015,
289, 313–330. [CrossRef] [PubMed]
28. Stevic, I.; Parmar, N.; Paredes, N.; Berry, L.R.; Chan, A.K.C. Binding of Heparin to Metals. Cell Biochem.
Biophys. 2011, 59, 171–178. [CrossRef] [PubMed]
29. Mulloy, B.; Forster, M.J.; Jones, C.; Drake, A.F.; Johnson, E.A.; Davies, D.B. The effect of variation of
substitution on the solution conformation of heparin: A spectroscopic and molecular modelling study.
Carbohydr. Res. 1994, 255, 1–26. [CrossRef]
30. Grant, D.; Long, W.F.; Moffat, C.F.; Williamson, F.B. Infrared spectroscopy of chemically modified heparins.
Biochem. J. 1989, 261, 1035–1038. [CrossRef] [PubMed]
Medicina 2019, 55, 636 14 of 19
31. van Boeckel, C.A.A.; van Aelst, S.F.; Wagenaars, G.N.; Mellema, J.R. Conformational analysis of synthetic
heparin-like oligosaccharides containing a-L-idopyranosyluronic acid. Recl. Trav. Chim. Pays-Bas 1987,
106, 19–29. [CrossRef]
32. Stancanelli, E.; Elli, S.; Hsieh, P.H.; Liu, J.; Guerrini, M. Recognition and Conformational Properties of
an Alternative Antithrombin Binding Sequence Obtained by Chemoenzymatic Synthesis. ChemBioChem
2018, 19, 1178–1188. [CrossRef] [PubMed]
33. Hricovíni, M.; Guerrini, M.; Bisio, A.; Torri, G.; Naggi, A.; Casu, B. Active conformations of
glycosaminoglycans. NMR determination of the conformation of heparin sequences complexed with
antithrombin and fibroblast growth factors in solution. Semin. Thromb. Hemost. 2002, 28, 325–334. [CrossRef]
[PubMed]
34. Rudd, T.; Yates, E.; Hricovini, M. Spectroscopic and Theoretical Approaches for the Determination of Heparin
Saccharide Structure and the Study of Protein-Glycosaminoglycan Complexes in Solution. Curr. Med. Chem.
2009, 16, 4750–4766. [CrossRef]
35. Mobli, M.; Nilsson, M.; Almond, A. The structural plasticity of heparan sulfate NA-domains and hence
their role in mediating multivalent interactions is confirmed by high-accuracy 15N-NMR relaxation studies.
Glycoconj. J. 2008, 25, 401–414. [CrossRef] [PubMed]
36. Ferro, D.R.; Provasoli, A.; Ragazzi, M.; Casu, B.; Torri, G.; Bossennec, V.; Perly, B.; Sinaÿ, P.; Petitou, M.;
Choay, J. Conformer populations of l-iduronic acid residues in glycosaminoglycan sequences. Carbohydr. Res.
1990, 195, 157–167. [CrossRef]
37. Hricovíni, M. Solution Structure of Heparin Pentasaccharide: NMR and DFT Analysis. J. Phys. Chem. B 2015,
119, 12397–12409. [CrossRef] [PubMed]
38. Rudd, T.R.; Guimond, S.E.; Skidmore, M.A.; Duchesne, L.; Guerrini, M.; Torri, G.; Cosentino, C.; Brown, A.;
Clarke, D.T.; Turnbull, J.E.; et al. Influence of substitution pattern and cation binding on conformation
and activity in heparin derivatives. Glycobiology 2007, 17, 983–993. [CrossRef] [PubMed]
39. Rabenstein, D.L.; Robert, J.M.; Peng, J. Multinuclear magnetic resonance studies of the interaction of inorganic
cations with heparin. Carbohydr. Res. 1995, 278, 239–256. [CrossRef]
40. Turnbull, J.E.; Hopwood, J.J.; Gallagher, J.T. A strategy for rapid sequencing of heparan sulfate and heparin
saccharides. Proc. Natl. Acad. Sci. USA 2002, 96, 2698–2703. [CrossRef]
41. Liu, H.; Zhang, Z.; Linhardt, R.J. Lessons learned from the contamination of heparin. Nat. Prod. Rep. 2009,
26, 313–321. [CrossRef] [PubMed]
42. Guerrini, M.; Bisio, A.; Torri, G. Combined Quantitative 1H and 13C Nuclear Magnetic Resonance
Spectroscopy for Characterization of Heparin Preparationsy. Semin. Thromb. Hemost. 2001, 27, 473–482.
[CrossRef] [PubMed]
43. Volpi, N.; Maccari, F.; Suwan, J.; Linhardt, R.J. Electrophoresis for the analysis of heparin purity and quality.
Electrophoresis 2012, 33, 1531–1537. [CrossRef] [PubMed]
44. Kishimoto, T.K.; Viswanathan, K.; Ganguly, T.; Elankumaran, S.; Smith, S.; Pelzer, K.; Lansing, J.C.;
Sriranganathan, N.; Zhao, G.; Galcheva-Gargova, Z.; et al. Contaminated Heparin Associated with Adverse
Clinical Events and Activation of the Contact System. N. Engl. J. Med. 2008, 358, 2457–2467. [CrossRef]
[PubMed]
45. Ramacciotti, E.; Clark, M.; Sadeghi, N.; Hoppensteadt, D.; Thethi, I.; Gomes, M.; Fareed, J. Contaminants in
heparin: Review of the literature, molecular profiling, and clinical implications. Clin. Appl. Thromb. 2011,
17, 126–135. [CrossRef]
46. Guerrini, M.; Beccati, D.; Shriver, Z.; Naggi, A.; Viswanathan, K.; Bisio, A.; Capila, I.; Lansing, J.C.; Guglieri, S.;
Fraser, B.; et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical
events. Nat. Biotechnol. 2008, 26, 669–675. [CrossRef]
47. Beyer, T.; Diehl, B.; Randel, G.; Humpfer, E.; Schäfer, H.; Spraul, M.; Schollmayer, C.; Holzgrabe, U.
Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy. J. Pharm.
Biomed. Anal. 2008, 48, 13–19. [CrossRef]
48. Fernandes, A. Heparin Sodium Monograph. Pharmacopeial Forum 2009, 34, 1–4.
49. Volpi, N.; Maccari, F.; Linhardt, R.J. Quantitative capillary electrophoresis determination of oversulfated
chondroitin sulfate as a contaminant in heparin preparations. Anal. Biochem. 2009, 388, 140–145. [CrossRef]
Medicina 2019, 55, 636 15 of 19
50. Alban, S.; Lühn, S.; Schiemann, S.; Beyer, T.; Norwig, J.; Schilling, C.; Rädler, O.; Wolf, B.; Matz, M.;
Baumann, K.; et al. Comparison of established and novel purity tests for the quality control of heparin by
means of a set of 177 heparin samples. Anal. Bioanal. Chem. 2011, 399, 605–620. [CrossRef]
51. Trehy, M.L.; Reepmeyer, J.C.; Kolinski, R.E.; Westenberger, B.J.; Buhse, L.F. Analysis of heparin sodium by
SAX/HPLC for contaminants and impurities. J. Pharm. Biomed. Anal. 2009, 49, 670–673. [CrossRef] [PubMed]
52. Szajek, A.Y.; Chess, E.; Johansen, K.; Gratzl, G.; Gray, E.; Keire, D.; Linhardt, R.J.; Liu, J.; Morris, T.;
Mulloy, B.; et al. The US regulatory and pharmacopeia response to the global heparin contamination crisis.
Nat. Biotechnol. 2016, 34, 625–630. [CrossRef] [PubMed]
53. Volpi, N.; Maccari, F. Electrophoretic approaches to the analysis of complex polysaccharides. J. Chromatogr. B
2006, 834, 1–13. [CrossRef] [PubMed]
54. Edens, R.E.; Al-Hakim, A.; Weiler, J.M.; Rethwisch, D.G.; Fareed, J.; Linhardt, R.J. Gradient polyacrylamide
gel electrophoresis for determination of molecular weights of heparin preparations and low-molecular-weight
heparin derivatives. J. Pharm. Sci. 1992, 81, 823–827. [CrossRef] [PubMed]
55. Zhang, Z.; Li, B.; Suwan, J.; Zhang, F.; Wang, Z.; Liu, H.; Mulloy, B.; Linhardt, R.J. Analysis of Pharmaceutical
Heparins and Potential Contaminants Using 1H-NMR and PAGE. J. Pharm. Sci. 2009, 98, 4017–4026.
[CrossRef]
56. Guerrini, M.; Zhang, Z.; Shriver, Z.; Naggi, A.; Masuko, S.; Langer, R.; Casu, B.; Linhardt, R.J.; Torri, G.;
Sasisekharan, R. Orthogonal analytical approaches to detect potential contaminants in heparin. Proc. Natl.
Acad. Sci. USA 2009, 106, 16956–16961. [CrossRef]
57. Keire, D.A.; Mans, D.J.; Ye, H.; Kolinski, R.E.; Buhse, L.F. Assay of possible economically motivated additives
or native impurities levels in heparin by 1H NMR, SAX-HPLC, and anticoagulation time approaches. J. Pharm.
Biomed. Anal. 2010, 52, 656–664. [CrossRef]
58. Spencer, J.A.; Kauffman, J.F.; Reepmeyer, J.C.; Gryniewicz, C.M.; Yi, W.; Duckhee, T.; Buhse, L.F.;
Westenberger, B.J. Screening of Heparin API by Near Infrared Reflectance and Raman Spectroscopy.
J. Pharm. Sci. 2009, 98, 3540–3547. [CrossRef]
59. Walenga, J.M.; Prechel, M.; Jeske, W.P.; Bakhos, M. Unfractionated heparin compared with
low-molecular-weight heparin as related to heparin-induced thrombocytopenia. Curr. Opin. Pulm. Med.
2005, 11, 385–391. [CrossRef]
60. Kakoi, N.; Kinoshita, M.; Kawasaki, N.; Yamaguchi, T.; Hayakawa, T.; Kakehi, K. Capillary Electrophoresis
Analysis of Contaminants in Heparin Sodium for the Japanese Pharmacopoeia Purity Test. Yakugaku Zasshi
2009, 129, 1255–1264. [CrossRef]
61. Wielgos, T.; Havel, K.; Ivanova, N.; Weinberger, R. Determination of impurities in heparin by capillary
electrophoresis using high molarity phosphate buffers. J. Pharm. Biomed. Anal. 2009, 49, 319–326. [CrossRef]
[PubMed]
62. Somsen, G.W.; Tak, Y.H.; Toraño, J.S.; Jongen, P.M.J.M.; de Jong, G.J. Determination of oversulfated chondroitin
sulfate and dermatan sulfate impurities in heparin by capillary electrophoresis. J. Chromatogr. A 2009,
1216, 4107–4112. [CrossRef] [PubMed]
63. Beni, S.; Limtiaco, J.F.K.; Larive, C.K. Analysis and characterization of heparin impurities. Anal. Bioanal. Chem.
2011, 399, 527–539. [CrossRef] [PubMed]
64. Volpi, N.; Buzzega, D. Agarose-gel electrophoresis for the quality assurance and purity of heparin formulations.
J. Pharm. Biomed. Anal. 2012, 67–68, 144–147. [CrossRef] [PubMed]
65. Hashii, N.; Kawasaki, N.; Itoh, S.; Qin, Y.; Fujita, N.; Hattori, T.; Miyata, K.; Bando, A.; Sekimoto, Y.;
Hama, T.; et al. Heparin identification test and purity test for OSCS in heparin sodium and heparin calcium
by weak anion-exchange high-performance liquid chromatography. Biologicals 2010, 38, 539–543. [CrossRef]
[PubMed]
66. Yang, B.; Solakyildirim, K.; Chang, Y.; Linhardt, R.J. Hyphenated techniques for the analysis of heparin
and heparan sulfate. Anal. Bioanal. Chem. 2011, 399, 541–557. [CrossRef] [PubMed]
67. Li, H.; Wickramasekara, S.; Nemes, P. One-Hour Screening of Adulterated Heparin by Simplified Peroxide
Digestion and Fast RPIP-LC-MS2. Anal. Chem. 2015, 87, 8424–8432. [CrossRef] [PubMed]
68. Ruiz-Calero, V.; Moyano, E.; Puignou, L.; Galceran, M.T. Pressure-assisted capillary electrophoresis-electrospray ion
trap mass spectrometry for the analysis of heparin depolymerised disaccharides. J. Chromatogr. A 2001, 914, 277–291.
[CrossRef]
Medicina 2019, 55, 636 16 of 19
69. Skidmore, M.A.; Guimond, S.E.; Dumax-Vorzet, A.F.; Yates, E.A.; Turnbull, J.E. Disaccharide compositional
analysis of heparan sulfate and heparin polysaccharides using UV or high-sensitivity fluorescence (BODIPY)
detection. Nat. Protoc. 2010, 5, 1983–1992. [CrossRef] [PubMed]
70. Holman, J.; Skidmore, M.A.; Rudd, T.R.; Yates, E.A. The latent ampholytic nature of glycosaminoglycan
(GAG) oligosaccharides facilitates their separation by isoelectric focusing. Anal. Methods 2010, 2, 1550–1554.
[CrossRef]
71. Volpi, N.; Maccari, F.; Linhardt, R.J. Capillary electrophoresis of complex natural polysaccharides.
Electrophoresis 2008, 29, 3095–3106. [CrossRef] [PubMed]
72. Zamfir, A.; Peter-Katalinic´, J. Capillary electrophoresis-mass spectrometry for glycoscreening in biomedical
research. Electrophoresis 2004, 25, 1949–1963. [CrossRef]
73. Nemes, P.; Hoover, W.J.; Keire, D.A. High-throughput differentiation of heparin from other
glycosaminoglycans by pyrolysis mass spectrometry. Anal. Chem. 2013, 85, 7405–7412. [CrossRef]
74. Harris, G.A.; Galhena, A.S.; Fern, F.M. Ambient Sampling/Ionization Mass Spectrometry: Applications
and Current Trends. Anal. Chem. 2011, 83, 4508–4538. [CrossRef] [PubMed]
75. Wang, Z.; Chi, L. Recent advances in mass spectrometry analysis of low molecular weight heparins.
Chin. Chem. Lett. 2018, 29, 11–18. [CrossRef]
76. Li, G.; Cai, C.; Li, L.; Fu, L.; Chang, Y.; Zhang, F.; Toida, T.; Xue, C.; Linhardt, R.J. Method to detect
contaminants in heparin using radical depolymerization and liquid chromatography-mass spectrometry.
Anal. Chem. 2014, 86, 326–330. [CrossRef]
77. Brustkern, A.M.; Buhse, L.F.; Nasr, M.; Al-Hakim, A.; Keire, D.A. Characterization of currently marketed
heparin products: Reversed-phase ion-pairing liquid chromatography mass spectrometry of heparin digests.
Anal. Chem. 2010, 82, 9865–9870. [CrossRef] [PubMed]
78. Lamari, F.N.; Kuhn, R.; Karamanos, N.K. Derivatization of carbohydrates for chromatographic, electrophoretic
and mass spectrometric structure analysis. J. Chromatogr. B 2003, 793, 15–36. [CrossRef]
79. Yates, E.A.; Santini, F.; Guerrini, M.; Naggi, A.; Torri, G.; Casu, B. 1H and 13C NMR spectral assignments of
the major sequences of twelve systematically modified heparin derivatives. Carbohydr. Res. 1996, 294, 15–27.
[CrossRef]
80. Langeslay, D.J.; Beecher, C.N.; Naggi, A.; Guerrini, M.; Torri, G.; Larive, C.K. Characterizing the microstructure
of heparin and heparan sulfate using N-sulfoglucosamine 1H and 15N NMR chemical shift analysis.
Anal. Chem. 2013, 85, 1247–1255. [CrossRef] [PubMed]
81. Langeslay, D.J.; Beni, S.; Larive, C.K. A closer look at the nitrogen next door: 1H-15N NMR methods for
glycosaminoglycan structural characterization. J. Magn. Reson. 2012, 216, 169–174. [CrossRef] [PubMed]
82. Neely, B.W. Infrared Spectra of Carbohydrates. Adv. Carbohyd. Chem. 1957, 12, 13–33.
83. Grant, D.; Long, W.F.; Williamson, F.B. Infrared spectroscopy of heparin-cation complexes. Biochem. J. 1987,
244, 143–149. [CrossRef]
84. Rudd, T.R.; Gaudesi, D.; Skidmore, M.A.; Ferro, M.; Guerrini, M.; Mulloy, B.; Torri, G.; Yates, E.A. Construction
and use of a library of bona fide heparins employing 1H NMR and multivariate analysis. Analyst 2011,
136, 1380–1389. [CrossRef]
85. Devlin, A.; Mycroft-West, C.; Guerrini, M.; Yates, E.; Skidmore, M. Analysis of solid-state heparin samples by
ATR-FTIR spectroscopy. bioRxiv 2019, 538074. [CrossRef]
86. Barlow, G.H. The determination of molecular weight distributions on heparin samples. Semin. Thromb.
Hemost. 1985, 11, 26–28. [CrossRef] [PubMed]
87. Malsch, R.; Harenberg, J. High-performance size exclusion chromatography and polyacrylamide gel
electrophoresis for characterization of unfractionated and low molecular mass glycosaminoglycans.
Semin. Thromb. Hemost. 1994, 20, 135–143. [CrossRef]
88. Bigler, P.; Brenneisen, R. Improved impurity fingerprinting of heparin by high resolution 1H NMR
spectroscopy. J. Pharm. Biomed. Anal. 2009, 49, 1060–1064. [CrossRef]
89. Sitkowski, J.; Bednarek, E.; Bocian, W.; Kozerski, L. Assessment of Oversulfated Chondroitin Sulfate in Low
Molecular Weight and Unfractioned Heparins Diffusion Ordered Nuclear Magnetic Resonance Spectroscopy
Method. J. Med. Chem. 2008, 51, 7663–7665. [CrossRef]
90. Spelta, F.; Liverani, L.; Peluso, A.; Marinozzi, M.; Urso, E.; Guerrini, M.; Naggi, A. SAX-HPLC and HSQC
NMR Spectroscopy: Orthogonal Methods for Characterizing Heparin Batches Composition. Front. Med.
2019, 6, 78. [CrossRef]
Medicina 2019, 55, 636 17 of 19
91. Stanley, F.E.; Stalcup, A.M. The use of circular dichroism as a simple heparin-screening strategy.
Anal. Bioanal. Chem. 2011, 399, 701–706. [CrossRef]
92. Stivala, S.S.; Herbst, M.; Kratky, O.; Pilz, I. Physico-chemical studies of fractionated bovine heparin.
Arch. Biochem. Biophys. 2004, 127, 795–802. [CrossRef]
93. Ly, M.; Wang, Z.; Laremore, T.N.; Zhang, F.; Zhong, W.; Pu, D.; Zagorevski, D.V.; Dordick, J.S.; Linhardt, R.J.
Analysis of E. coli K5 capsular polysaccharide heparosan. Anal. Bioanal. Chem. 2011, 399, 737–745. [CrossRef]
[PubMed]
94. Sommers, C.D.; Ye, H.; Kolinski, R.E.; Nasr, M.; Buhse, L.F.; Al-Hakim, A.; Keire, D.A. Characterization
of currently marketed heparin products: Analysis of molecular weight and heparinase-I digest patterns.
Anal. Bioanal. Chem. 2011, 401, 2445–2454. [CrossRef]
95. Rodriguez, H.J.; Vanderwielen, A.J. Molecular weight determination of commercial heparin sodium USP
and its sterile solutions. J. Pharm. Sci. 1979, 68, 588–591. [CrossRef] [PubMed]
96. Ahsan, A.; Jeske, W.; Hoppensteadt, D.; Lormeau, J.C.; Wolf, H. Molecular profiling and weight determination
of heparins and depolymerized heparins. J. Pharm. Sci. 1995, 84, 724–727. [CrossRef]
97. Guo, X.; Condra, M.; Kimura, K.; Berth, G.; Dautzenberg, H.; Dubin, P.L. Determination of molecular weight
of heparin by size exclusion chromatography with universal calibration. Anal. Biochem. 2003, 312, 33–39.
[CrossRef]
98. Knobloch, J.E.; Shaklee, P.N. Absolute molecular weight distribution of low-molecular-weight heparins
by size-exclusion chromatography with multiangle laser light scattering detection. Anal. Biochem. 1997,
245, 231–241. [CrossRef]
99. Beirne, J.; Truchan, H.; Rao, L. Development and qualification of a size exclusion chromatography coupled
with multiangle light scattering method for molecular weight determination of unfractionated heparin.
Anal. Bioanal. Chem. 2011, 399, 717–725. [CrossRef]
100. Barlow, G.H.; Sanderson, N.D.; McNeill, P.D. Macromolecular properties and biological activity of heparin.
Arch. Biochem. Biophys. 1961, 94, 518–525. [CrossRef]
101. Desai, U.R.; Linhardt, R.J. Molecular Weight of Heparin Using. J. Pharm. Sci. 1995, 84, 212–215. [CrossRef]
[PubMed]
102. Juhasz, P.; Biemann, K. Mass spectrometric molecular-weight determination of highly acidic compounds of biological
significance via their complexes with basic polypeptides. Proc. Natl. Acad. Sci. USA 1994, 91, 4333–4337. [CrossRef]
[PubMed]
103. Chi, L.; Amster, J.; Linhardt, R. Mass Spectrometry for the Analysis of Highly Charged Sulfated Carbohydrates.
Curr. Anal. Chem. 2005, 1, 223–240. [CrossRef]
104. Bertini, S.; Bisio, A.; Torri, G.; Bensi, D.; Terbojevich, M. Molecular weight determination of heparin
and dermatan sulfate by size exclusion chromatography with a triple detector array. Biomacromolecules 2005,
6, 168–173. [CrossRef] [PubMed]
105. Viskov, C.; Bouley, E.; Hubert, P.; Martinez, C.; Herman, F.; Jeske, W.; Hoppensteadt, D.;
Walenga, J.M.; Fareed, J. Isolation and characterization of contaminants in recalled unfractionated heparin
and low-molecular-weight heparin. Clin. Appl. Thromb. 2009, 15, 395–401. [CrossRef] [PubMed]
106. Tami, C.; Puig, M.; Reepmeyer, J.C.; Ye, H.; Avignon, D.A.; Buhse, L.; Verthelyi, D. Inhibition of Taq polymerase
as a method for screening heparin for oversulfated contaminants. Biomaterials 2008, 29, 4808–4814. [CrossRef]
[PubMed]
107. Sommers, C.D.; Mans, D.J.; Mecker, L.C.; Keire, D.A. Sensitive detection of oversulfated chondroitin sulfate in
heparin sodium or crude heparin with a colorimetric microplate based assay. Anal. Chem. 2011, 83, 3422–3430.
[CrossRef] [PubMed]
108. Ding, Y.; Shi, L.; Wei, H. A “turn on” fluorescent probe for heparin and its oversulfated chondroitin sulfate
contaminant. Chem. Sci. 2015, 6, 6361–6366. [CrossRef] [PubMed]
109. Ding, Y.; Zhou, M.; Wei, H. A supercharged fluorescent protein based FRET sensing platform for detection of
heparin contamination. Anal. Methods 2017, 9, 5593–5597. [CrossRef]
110. Hu, Y.; Guo, W.; Ding, Y.; Cheng, H.; Wei, H. Modulating luminescence of Tb3+ with biomolecules for
sensing heparin and its contaminant OSCS. Biosens. Bioelectron. 2016, 86, 858–863. [CrossRef]
111. Kalita, M.; Balivada, S.; Swarup, V.P.; Mencio, C.; Raman, K.; Desai, U.R.; Troyer, D.; Kuberan, B. A nanosensor
for ultrasensitive detection of oversulfated chondroitin sulfate contaminant in heparin. J. Am. Chem. Soc.
2014, 136, 554–557. [CrossRef] [PubMed]
Medicina 2019, 55, 636 18 of 19
112. Lühn, S.; Schiemann, S.; Alban, S. Simple fluorescence assay for quantification of OSCS in heparin.
Anal. Bioanal. Chem. 2011, 399, 673–680. [CrossRef] [PubMed]
113. Alban, S.; Lühn, S.; Schiemann, S. Combination of a two-step fluorescence assay and a two-step anti-Factor Xa assay for
detection of heparin falsifications and protein in heparins. Anal. Bioanal. Chem. 2011, 399, 681–690. [CrossRef] [PubMed]
114. Lee, C.Y.; Tseng, W.L. Molecular beacon-based fluorescent assay for specific detection of oversulfated
chondroitin sulfate contaminants in heparin without enzyme treatment. Anal. Chem. 2015, 87, 5031–5035.
[CrossRef] [PubMed]
115. Wang, L.; Buchanan, S.; Meyerhoff, M.E. Detection of high-charge density polyanion contaminants in
biomedical heparin preparations using potentiometric polyanion sensors. Anal. Chem. 2008, 80, 9845–9847.
[CrossRef] [PubMed]
116. Rudd, T.R.; MacChi, E.; Gardini, C.; Muzi, L.; Guerrini, M.; Yates, E.A.; Torri, G. How to find a needle
(or anything else) in a haystack: Two-dimensional correlation spectroscopy-filtering with iterative random
sampling applied to pharmaceutical heparin. Anal. Chem. 2012, 84, 6841–6847. [CrossRef] [PubMed]
117. Zang, Q.; Keire, D.A.; Wood, R.D.; Buhse, L.F.; Moore, C.M.V.; Nasr, M.; Al-Hakim, A.; Trehy, M.L.; Welsh, W.J.
Combining 1H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan
sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants. J. Pharm. Biomed. Anal.
2011, 54, 1020–1029. [CrossRef]
118. Lima, M.A.; Rudd, T.R.; de Farias, E.H.C.; Ebner, L.F.; Gesteira, T.F.; de Souza, L.M.; Mendes, A.; Córdula, C.R.;
Martins, J.R.M.; Hoppensteadt, D.; et al. A new approach for heparin standardization: Combination of
scanning UV spectroscopy, nuclear magnetic resonance and principal component analysis. PLoS ONE 2011,
6, e15970. [CrossRef]
119. Zang, Q.; Keire, D.A.; Buhse, L.F.; Wood, R.D.; Mital, D.P.; Haque, S.; Srinivasan, S.; Moore, C.M.V.; Nasr, M.;
Al-Hakim, A.; et al. Identification of heparin samples that contain impurities or contaminants by chemometric
pattern recognition analysis of proton NMR spectral data. Anal. Bioanal. Chem. 2011, 401, 939–955. [CrossRef]
120. Rudd, T.R.; Mauri, L.; Marinozzi, M.; Stancanelli, E.; Yates, E.; Naggi, A.; Guerrini, M. Multivariate analysis
applied to complex biological medicines. Faraday Discuss. 2019, 218, 303–316. [CrossRef]
121. Monakhova, Y.B.; Fareed, J.; Yao, Y.; Diehl, B.W.K. Improving reliability of chemometric models for
authentication of species origin of heparin by switching from 1D to 2D NMR experiments. J. Pharm. Biomed.
Anal. 2018, 153, 168–174. [CrossRef]
122. Mauri, L.; Marinozzi, M.; Mazzini, G.; Kolinski, R.E.; Karfunkle, M.; Keire, D.A.; Guerrini, M. Combining
NMR Spectroscopy and Chemometrics to Monitor Structural Features of Crude Hep-arin. Molecules 2017,
22, 1146. [CrossRef] [PubMed]
123. Keire, D.A.; Trehy, M.L.; Reepmeyer, J.C.; Kolinski, R.E.; Ye, W.; Dunn, J.; Westenberger, B.J.; Buhse, L.F.
Analysis of crude heparin by 1H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for
contamination by over sulfated chondroitin sulfate. J. Pharm. Biomed. Anal. 2010, 51, 921–926. [CrossRef]
[PubMed]
124. Rudd, T.R.; Skidmore, M.A.; Guimond, S.E.; Guerrini, M.; Cosentino, C.; Edge, R.; Brown, A.; Clarke, D.T.;
Torri, G.; Turnbull, J.E.; et al. Site-specific interactions of copper (II) ions with heparin revealed with
complementary (SRCD, NMR, FTIR and EPR) spectroscopic techniques. Carbohydr. Res. 2008, 343, 2184–2193.
[CrossRef]
125. Schwçrer, R.; Zubkova, O.V.; Turnbull, J.E.; Tyler, P.C. Synthesis of a Targeted Library of Heparan Sulfate
Hexa- to Dodecasaccharides as Inhibitors of β-Secretase: Potential Therapeutics for Alzheimer s Disease.
Chem. Eur. J. 2013, 19, 6817–6823.
126. Wang, Z.; Hsieh, P.; Xu, Y.; Thieker, D.; En, E.J.; Xie, S.; Cooley, B.; Woods, R.J.; Chi, L.; Liu, J.; et al. Synthesis
of 3-O-sulfated oligosaccharides to understand the relationship between structures and functions of heparan
sulfate. J. Am. Chem. Soc. 2018, 139, 5249–5256. [CrossRef] [PubMed]
127. Gao, W.; Xu, Y.; Liu, J.; Ho, M. Epitope mapping by a Wnt-blocking antibody: Evidence of the Wnt binding
domain in heparan sulfate. Sci. Rep. 2016, 6, 26245. [CrossRef] [PubMed]
Medicina 2019, 55, 636 19 of 19
128. Zhang, Z.; Mccallum, S.A.; Xie, J.; Nieto, L.; Corzana, F.; Chen, M.; Liu, J.; Linhardt, R.J. Solution Structures
of Chemoenzymatically Synthesized Heparin and Its Precursors. J. Am. Chem. Soc. 2009, 130, 12998–13007.
[CrossRef]
129. Keire, D.A.; Ye, H.; Trehy, M.L.; Ye, W.; Kolinski, R.E.; Westenberger, B.J.; Buhse, L.F.; Nasr, M.; Al-Hakim, A.
Characterization of currently marketed heparin products: Key tests for quality assurance. Anal. Bioanal. Chem.
2011, 399, 581–591. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
